Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
Philip J Mease, MD: Efficacy of Guselkumab for Reducing Fatigue in Psoriatic Arthritis
August 4th 2021Philip J Mease, MD, discusses his study, “Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.”
Read More
Elderly-Onset Rheumatoid Arthritis DMARD Response Similar to Non-EORA Counterparts
July 30th 2021After controlling for variables, eldery-onset rheumatoid arthritis (EORA) was not indicative of changes in Clinical Disease Activity Index (CDAI) scores over time when compared with a non-EORA cohort. Further, there were no significant differences in the efficacy and safety of receiving biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).
Read More
Expert Perspectives: Improved Medication Adherence in Rheumatic Diseases
July 29th 2021“Our study confirms challenges in selecting an appropriate outcome in interventional studies targeting medication adherence and the ways in which the lack of guidance in this area hinders research and limits our ability to compare interventions and draw conclusions about their effectiveness,” stated investigators.
Read More
Targeted Biologics Did Not Affect Humoral Immunity to First Dose of COVID-19 Vaccine
July 29th 2021Common immunosuppressant therapies for patients with rheumatic disease, such as methotrexate and targeted biologics, increase risk of serious infection, especially with respiratory pathogens. A recent study investigates the connection between these drugs and functional humoral immunity to the first dose of the COVID-19 vaccine BNT162b2 (Pfizer-BioNTech).
Read More
Lower Anti-Vaccine Antibody Levels Observed in Patients With Juvenile Idiopathic Arthritis
July 28th 2021Many children with juvenile idiopathic arthritis stop vaccinating when diagnosis is established, despite them being at a greater risk of infections than healthy children due to their aberrant immunity and the use of immunosuppressive drugs.
Read More
Roy Fleischmann, MD: Safety of JAK Inhibitors
July 27th 2021Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients.
Read More
Cardiovascular Autonomic Neuropathy Associated with Impaired Quality of Life in Patients with Lupus
July 26th 2021Patients with systemic lupus erythematosus presented more cardiovascular autonomic neuropathy, along with impaired health-related quality of life and parasympathetic function, when compared with a control cohort.
Read More
PainTRAINER Program Improves Outcomes for Patients With Systemic Lupus Erythematosus
July 22nd 2021The painTRAINER program included 8 weekly modules, in addition to coping skill activities, in which investigators measured outcomes including the Pain Catastrophizing Scale, pain interference, physical function, anxiety and depression, fatigue, and sleep disturbances.
Read More
Investigators analyzed the effect of biologic therapies in order to determine the effectiveness of this first-line biologic approach in treating systemic juvenile idiopathic arthritis (sJIA) and reducing the exposure of glucocorticoids, a driver of morbidity in this patient population.
Read More
Low Prevalence of Anti-SSA/B in Women With Rheumatoid Arthritis Wishing to Conceive
July 15th 2021Given the low prevalence of anti-Sjögren's-syndrome-related antigen A (anti-SSA) and anti–Sjögren's-syndrome-related antigen B (anti-SSB) in women with rheumatoid arthritis who would like to conceive, intensive echocardiographic screening may not be necessary.
Read More
Erectile Dysfunction Decreases Risk of Cardiovascular Events in Patients With Rheumatoid Arthritis
July 14th 2021Surprisingly, patients with rheumatoid arthritis and erectile dysfunction had a significantly decreased rate of myocardial infarction, heart failure, and death when compared with patients with rheumatoid arthritis alone.
Read More
Tofacitinib and Adalimumab Significantly Improved Pain for Patients With Psoriatic Arthritis
July 13th 2021“This analysis provides information on when clinically meaningful improvements in pain may be expected in patients with psoriatic arthritis receiving tofacitinib or adalimumab, and how baseline pain severity may impact response to tofacitinib, which is of value in clinical practice,” stated investigators.
Read More
Overdrive Podcast: Value-Based Care in Rheumatology
July 13th 2021On the latest episode of Overdrive, we sat down with Andrew L Concoff MD, FACR, CAQSM, to discuss value-based care, including the benefits, collaborate approach to working with payers, the revenue and cost savings, and how value-based care can support routine and consistent health visits.
Read More
Richard Furie, MD: Safety and Efficacy of BIIB059 for Systemic Lupus Erythematosus
July 9th 2021Richard Furie, MD, explains the safety and efficacy of BIIB059 for patients with systemic lupus erythematosus (SLE), the study design and background on his upcoming SLE study, and Biogen’s ongoing commitment to including underrepresented groups in its clinical trials.
Read More
Christopher Ritchlin, MD, MPH: Safety and Efficacy of Bimekizumab for Psoriatic Arthritis
July 5th 2021Christopher Ritchlin, MD, MPH, discusses the safety and efficacy of bimekizumab in patients with psoriatic arthritis, the BE ACTIVE study, the clinical significance of these results, and his plans for future research on this topic.
Read More